The PPAR alpha pathway in V gamma 9V delta 2 T cell anergy

• Autorzy: Poupot M. , Boissard F. , Betous D. , Bardouillet L. , Fruchon S. , L Faqihi-olive F. , Pont F. , Mekaouche M. , Ingoure S. , Sicard H. , Dubreuilh G. , Fournie J.-J.
• Języki publikacji: EN

Abstrakty

EN

Phosphoantigens (PAgs) activate Vγ9Vδ2 T lymphocytes, inducing their potent and rapid response in vitro and in vivo. However, humans and nonhuman primates that receive repeated injections of PAgs progressively lose their Vγ9Vδ2 T cell response to them. To elucidate the molecular mechanisms of this in vivo desensitization, we analyzed the transcriptome of circulating Vγ9Vδ2 T cells from macaques injected with PAg. We showed that three PAg injections induced the activation of the PPARα pathway in Vγ9Vδ2 T cells. Thus, we analyzed the in vitro response of Vγ9Vδ2 T cells stimulated with a PPARα agonist. We demonstrated that in vitro PPARα pathway activation led to the inhibition of the BrHPP-induced activation and proliferation of human Vγ9Vδ2 T cells. Since the PPARα pathway is involved in the antigen-selective desensitization of human Vγ9Vδ2 T cells, the use of PPARα inhibitors could enhance cancer immunotherapy based on Vγ9Vδ2 T cells.

Słowa kluczowe

EN

immunotherapy; peroxisome proliferator-activated receptor; interleukin 2; proliferation; T cell; T lymphocyte

• Wydawca: -
• Czasopismo: Cellular and Molecular Biology Letters
• Rocznik: 2014
• Tom: 19
• Numer: 4
• Opis fizyczny: p.649-658,fig.,ref.

Twórcy

autor

Poupot M.

• Inserm UMR1037-Cancer Research Center of Toulouse, CHU Purpan, F-31300, Toulouse, France
• ERL 5294 CNRS, CHU Purpan, BP3028, F-31300, Toulouse, France
• Universite Toulouse III Paul-Sabatier, 31300, Toulouse, France

autor

Boissard F.

• Inserm UMR1037-Cancer Research Center of Toulouse, CHU Purpan, F-31300, Toulouse, France
• ERL 5294 CNRS, CHU Purpan, BP3028, F-31300, Toulouse, France
• Universite Toulouse III Paul-Sabatier, 31300, Toulouse, France

autor

Betous D.

• Inserm UMR1037-Cancer Research Center of Toulouse, CHU Purpan, F-31300, Toulouse, France
• ERL 5294 CNRS, CHU Purpan, BP3028, F-31300, Toulouse, France
• Universite Toulouse III Paul-Sabatier, 31300, Toulouse, France

autor

Bardouillet L.

• Station de Primatologie, UPS 846, Centre National de la Recherche Scientifique, F-13790, Rousset sur Arc, France

autor

Fruchon S.

• INSERM U1043-CPTP Toulouse, F-31300, Toulouse, France 6. Innate Pharma, F-13276, Marseille, France

autor

L Faqihi-olive F.

• INSERM U1043-CPTP Toulouse, F-31300, Toulouse, France 6. Innate Pharma, F-13276, Marseille, France

autor

Pont F.

• INSERM UMR1037-Cancer Research Center of Toulouse, CHU Purpan, F-31300, Toulouse, France

autor

Mekaouche M.

• Station de Primatologie, UPS 846, Centre National de la Recherche Scientifique, F-13790, Rousset sur Arc, France

autor

Ingoure S.

• Innate Pharma, F-13276, Marseille, France

autor

Sicard H.

• Innate Pharma, F-13276, Marseille, France

autor

Dubreuilh G.

• Station de Primatologie, UPS 846, Centre National de la Recherche Scientifique, F-13790, Rousset sur Arc, France

autor

Fournie J.-J.

• INSERM UMR1037-Cancer Research Center of Toulouse, CHU Purpan, F-31300, Toulouse, France
• ERL 5294 CNRS, CHU Purpan, BP3028, F-31300, Toulouse, France
• Universite Toulouse III Paul-Sabatier, 31300, Toulouse, France 4. Station de Primatologie, UPS 846, Centre

Bibliografia

• 1. Angelini, D.F., Borsellino, G., Poupot, M, Diamantini, A., Poupot, R., Bernardi, G., Poccia, F., Fournie, J. J. and Battistini, L. FcgammaRIII discriminates between 2 subsets of Vgamma9Vdelta2 effector cells with different responses and activation pathways. Blood 104 (2004) 1801-1807.
• 2. Rothenfusser, S., Buchwald, A., Kock, S., Ferrone, S. and Fisch, P. Missing HLA class I expression on Daudi cells unveils cytotoxic and proliferative responses of human gammadelta T lymphocytes. Cell. Immunol. 215 (2002) 32-44.
• 3. Kunzmann, V. and Wilhelm, M. Anti-lymphoma effect of gammadelta T cells. Leuk. Lymphoma 46 (2005) 671-680.
• 4. Bonneville, M. and Scotet, E. Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors. Curr. Opin. Immunol. 18 (2006) 539-546.
• 5. Kabelitz, D., Wesch, D. anf He, W. Perspectives of gammadelta T cells in tumor immunology. Cancer Res. 67 (2007) 5-8.
• 6. Caccamo, N., Meraviglia, S., Cicero, G., Gulotta, G., Moschella, F., Cordova, A., Gulotta, E., Salerno, A. and Dieli, F. Aminobisphosphonates as new weapons for gammadelta T cell-based immunotherapy of cancer. Curr. Med. Chem. 15 (2008) 1147-1153.
• 7. Sicard, H., Ingoure, S., Luciani, B., Serraz, C., Fournie, J.J., Bonneville, M., Tiollier, J. and Romagne, F. In vivo immunomanipulation of V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J. Immunol. 175 (2005) 5471-5480.
• 8. Cendron, D., Ingoure, S., Martino, A., Casetti, R., Horand, F., Romagne, F., Sicard, H., Fournie, J.J. and Poccia, F. A tuberculosis vaccine based on phosphoantigens and fusion proteins induces distinct gammadelta and alphabeta T cell responses in primates. Eur. J. Immunol. 37 (2007) 549-565.
• 9. Sicard, H., Rossi, JP., Rousselot, P., Colette, A., Paiva C., Ingoure, S. and Lafaye de Micheaux, S. Cognitive study of reactivity to IPH1101 of peripheral  T lymphocytes from chronic myeloid leukemia, multiple myeloma and follicular lymphoma patients. ASH Annual Meeting Abstracts 112 (2008) 1530.
• 10. Barbier, O., Torra, I.P., Duguay, Y., Blanquart, C., Fruchart, J.C., Glineur, C. and Staels, B. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 717-726.
• 11. Daynes, R.A. and Jones, D.C. Emerging roles of PPARs in inflammation and immunity. Nat. Rev. Immunol. 2 (2002) 748-759.
• 12. Delerive, P., De Bosscher, K., Besnard, S., Vanden Berghe, W., Peters, J.M., Gonzalez, F. J., Fruchart, J.C., Tedgui, A., Haegeman, G. and Staels, B. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J. Biol. Chem. 274 (1999) 32048-32054.
• 13. Zhang, M.A., Rego, D., Moshkova, M., Kebir, H., Chruscinski, A., Nguyen, H., Akkermann, R., Stanczyk, F.Z., Prat, A., Steinman, L. and Dunn, S.E. Peroxisome proliferator-activated receptor (PPAR)alpha and -gamma regulate IFNgamma and IL-17A production by human T cells in a sexspecific way. Proc. Natl. Acad. Sci. USA 109 (2012) 9505-9510.
• 14. Martinet, L., Poupot, R. and Fournie, J.J. Pitfalls on the roadmap to gammadelta T cell-based cancer immunotherapies. Immunol. Lett. 124 (2009) 1-8.
• 15. Capietto, A.H., Martinet, L. and Fournie, J.J. How tumors might withstand gammadelta T-cell attack. Cell. Mol. Life Sci. 68 (2011) 2433-2442.
• 16. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S. and Mesirov, J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102 (2005) 15545-15550.
• 17. Boullier, S., Poquet, Y., Debord, T., Fournie, J.J. and Gougeon, M.L. Regulation by cytokines (IL-12, IL-15, IL-4 and IL-10) of the Vgamma9Vdelta2 T cell response to mycobacterial phosphoantigens in responder and anergic HIV-infected persons. Eur. J. Immunol. 29 (1999) 90-99.
• 18. Martini, F., Paglia, M.G., Montesano, C., Enders, P.J., Gentile, M., Pauza, C.D., Gioia, C., Colizzi, V., Narciso, P., Pucillo, L.P. and Poccia, F. V gamma 9V delta 2 T-cell anergy and complementarity-determining region 3-specific depletion during paroxysm of nonendemic malaria infection. Infect. Immun. 71 (2003) 2945-2949.
• 19. Montesano, C., Gioia, C., Martini, F., Agrati, C., Cairo, C., Pucillo, L.P., Colizzi, V. and Poccia, F. Antiviral activity and anergy of gammadeltaT lymphocytes in cord blood and immuno-compromised host. J. Biol. Regul. Homeost. Agents 15 (2001) 257-264.
• 20. Luna-Gomes, T., Bozza, P.T. and Bandeira-Melo, C. Eosinophil recruitment and activation: the role of lipid mediators. Front. Pharmacol. 4 (2013) 27.
• 21. Montuschi, P. LC/MS/MS analysis of leukotriene B4 and other eicosanoids in exhaled breath condensate for assessing lung inflammation. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 877 (2009) 1272-1280.
• 22. Hou, X., Shen, Y.H., Li, C., Wang, F., Zhang, C., Bu, P. and Zhang, Y. PPARalpha agonist fenofibrate protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress and MAPK activity. Biochem. Biophys. Res. Commun. 394 (2010) 653-659.
• 23. Mendler, A.N., Hu, B., Prinz, P.U., Kreutz, M., Gottfried, E. and Noessner, E. Tumor lactic acidosis suppresses CTL function by inhibition of p38 and JNK/c-Jun activation. Int. J. Cancer 131 (2012) 633-640.
• 24. Lim, W.S., Ng, D.L., Kor, S.B., Wong, H.K., Tengku-Muhammad, T.S., Choo, Q.C. and Chew, C.H. Tumour necrosis factor alpha down-regulates the expression of peroxisome proliferator activated receptor alpha (PPARalpha) in human hepatocarcinoma HepG2 cells by activation of NF-kappaB pathway. Cytokine 61 (2013) 266-274.
• 25. Ammazzalorso, A., D'Angelo, A., Giancristofaro, A., De Filippis, B., Di Matteo, M., Fantacuzzi, M., Giampietro, L., Linciano, P., Maccallini, C. and Amoroso, R. Fibrate-derived N-(methylsulfonyl)amides with antagonistic properties on PPARalpha. Eur. J. Med. Chem. 58 (2012) 317-322.
• 26. el Azzouzi, H., Leptidis, S., Bourajjaj, M., van Bilsen, M., da Costa Martins, P.A. and De Windt, L.J. MEK1 inhibits cardiac PPARalpha activity by direct interaction and prevents its nuclear localization. PLoS One 7 (2012) e36799.
• 27. Sozio, M.S., Lu, C., Zeng, Y., Liangpunsakul, S. and Crabb, D.W. Activated AMPK inhibits PPAR-{alpha} and PPAR-{gamma} transcriptional activity in hepatoma cells. Am. J. Physiol. Gastrointest. Liver Physiol. 301 (2011) G739-747.
• 28. Tung, S., Shi, Y., Wong, K., Zhu, F., Gorczynski, R., Laister, R.C., Minden, M., Blechert, A.K., Genzel, Y., Reichl, U. and Spaner, D.E. PPARalpha and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia. Blood 122 (2013) 969-980.

Identyfikatory

DOI

10.2478/s11658-014-0218-0